CD19 and acute myeloid leukemia: As observed in previous experiments, with no AML or CAR T cell administration, both editing groups showed similar peripheral blood composition (Extended Data Fig. 9a), editing levels comparable to input cells (around 85%), which remained stable over time, and a lack of differences within the BM myeloid and lymphoid subsets (sorted CD33+ and CD19+ cells, respectively) (Fig. 4b).